Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.1037 |
| Open | 0.1037 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1000 - 0.1138 |
| 52 Week Range | 0.1000 - 0.6045 |
| Volume | 96,405 |
| Avg. Volume | 114,890 |
| Market Cap | 31.856M |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0290 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- ACCESSWIRE
Tetra Bio-Pharma Adds Two Board Members and Appoints New COO
OTTAWA, ON / ACCESSWIRE / September 17, 2020 / Tetra Bio-Pharma Inc.
- ACCESSWIRE
Tetra Bio-Pharma Appoints Chief Financial Officer
OTTAWA, ON / ACCESSWIRE / September 11, 2020 / Tetra Bio-Pharma Inc.
- ACCESSWIRE
Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy
Brings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis spaceOTTAWA, ON / ACCESSWIRE / September 4, 2020 / Tetra Bio-Pharma Inc.
© 2020 Verizon Media. All rights reserved.
